Northern Trust Corp Trims Stake in OptiNose, Inc. (NASDAQ:OPTN)

Northern Trust Corp cut its stake in OptiNose, Inc. (NASDAQ:OPTN) by 94.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,085 shares of the company’s stock after selling 239,472 shares during the period. Northern Trust Corp’s holdings in OptiNose were worth $94,000 as of its most recent SEC filing.

Analyst Ratings Changes

OPTN has been the subject of several recent analyst reports. Piper Sandler reaffirmed a “neutral” rating and set a $9.00 price objective (down from $15.00) on shares of OptiNose in a research note on Friday, March 21st. HC Wainwright reaffirmed a “neutral” rating and set a $9.00 target price on shares of OptiNose in a research note on Monday, May 19th. Finally, Lake Street Capital cut shares of OptiNose from a “buy” rating to a “hold” rating and dropped their price target for the stock from $17.00 to $9.00 in a research note on Thursday, March 20th.

OptiNose Stock Performance

OPTN stock opened at $9.60 on Wednesday. The firm has a 50 day moving average of $9.33 and a 200-day moving average of $7.43. The company has a market cap of $97.22 million, a price-to-earnings ratio of -2.29 and a beta of -0.88. OptiNose, Inc. has a 12-month low of $4.82 and a 12-month high of $20.03.

OptiNose (NASDAQ:OPTN) last issued its earnings results on Tuesday, May 13th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.27). The firm had revenue of $18.51 million for the quarter, compared to analyst estimates of $17.70 million. Sell-side analysts forecast that OptiNose, Inc. will post -3.22 earnings per share for the current fiscal year.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.